Skip to content
Acting Auditions – Lifestyle
Author:
Amplia Therapuetics Limited
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
May 19, 2026
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
May 8, 2026
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
March 23, 2026
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
March 9, 2026